US Falls Behind in Facilitating New Antibiotics Pipeline - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

US Falls Behind in Facilitating New Antibiotics Pipeline

According to a report by GlobalData, although the Generating Antibiotic Incentives Now (GAIN) Act of 2012 was a step in the right direction for encouraging antibiotics research, FDA still lags behind EMA.

Marc C. Hansel, PhD, GlobalData’s analyst covering infectious diseases, says that the GAIN Act has catalyzed investment from companies in the antibiotics business and has strengthened a stagnant pipeline, with the recent expedited approvals of two new drugs, Sivextro and Dalvance. Although these developments are positive, GlobalData believes that a number of unmet needs remain within the bacterial infectious diseases area, with new treatments for multidrug-resistant (MDR) gram-negative bacteria in particularly high demand.

Despite FDA making advances in incentivizing companies to develop antimicrobial therapies, GlobalData believes that the agency needs to continue taking proactive action if it is to keep pace with progressive regulatory bodies in the EU, particularly the EMA. The latter organization has shown greater willingness to reform clinical trial design for new antibiotics and provide guidance that prioritizes clinical feasibility.

“The FDA will need to continue refining its practices in order to maintain a robust antibiotic pipeline and offer flexibility to encourage the targeting of the most dangerous pathogens. Crucially, the FDA must do more to further draw the vast research and development resources of Big Pharma into the antibiotics market by maximizing its commercial viability,” said Hansel.

Source: GlobalData


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here